Vaxcyte's stock surges on promising vaccine data, offering potential upside despite competition. Learn more on PCVX here.

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

STAT's podcast The Readout LOUD this week discusses cannabinoid receptor drugs in weight loss, what the Fed's rates cut might ...

There is a new pressure group in town. This particular benighted and besieged minority? Britain’s super rich, also known as ...

“The Secretary strongly reemphasized the importance of reaching a diplomatic resolution that enables residents to return ...

First developed for the Large Hadron Collider, hybrid pixel detectors are now changing the face of X-ray imaging in medical ...

Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...

Wilde, a Bloomberg UK journalist and editor on the Readout. Hope you enjoy today’s newsletter. Well, what a pivot week this ...

Viking Therapeutics (VKTX) stock rises as J.P. Morgan gives a buy-equivalent rating on upcoming Phase 1 trial results for ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80.

Keysight Technologies, Inc. (NYSE: KEYS) introduces Quantum Circuit Simulation (Quantum Ckt Sim), an innovative circuit design environment that speeds ...